Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gugliotta

Showing results (421-430 of 469) with videos related to

Pageof 47
Sort By:
Cardiovascular Research|February 18, 2020
Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trialDavid Corcoran, Aleksandra Radjenovic, Ify R Mordi, et al.
Targeted Oncology|October 18, 2021
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management ToolsFausto Castagnetti, Gianni Binotto, Isabella Capodanno, et al.
Blood|October 14, 2009
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemiaGianantonio Rosti, Francesca Palandri, Fausto Castagnetti, et al.
Annals of Hematology|July 8, 2009
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutationValerio De Stefano, Tommaso Za, Elena Rossi, et al.
American Journal of Hematology|April 10, 2026
A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell LymphomaGabriele Gugliotta, Lisa Argnani, Martina Cantelli, et al.
Blood|March 24, 2007
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemiaAlessandro M Vannucchi, Elisabetta Antonioli, Paola Guglielmelli, et al.
Leukemia Research|July 19, 2011
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemiaLuigi Gugliotta, Alessia Tieghi, Giovanni Tortorella, et al.
Leukemia|December 2, 2020
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGSSimona Soverini, Margherita Martelli, Luana Bavaro, et al.
Haematologica|February 13, 2008
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatmentsValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2014
Differences among young adults, adults and elderly chronic myeloid leukemia patientsF Castagnetti, G Gugliotta, M Baccarani, et al.
Pageof 47

Showing results (421-430 of 469) with videos related to

Sort By:
Pageof 47
Cardiovascular Research|February 18, 2020
Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trialDavid Corcoran, Aleksandra Radjenovic, Ify R Mordi, et al.
Targeted Oncology|October 18, 2021
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management ToolsFausto Castagnetti, Gianni Binotto, Isabella Capodanno, et al.
Blood|October 14, 2009
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemiaGianantonio Rosti, Francesca Palandri, Fausto Castagnetti, et al.
Annals of Hematology|July 8, 2009
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutationValerio De Stefano, Tommaso Za, Elena Rossi, et al.
American Journal of Hematology|April 10, 2026
A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell LymphomaGabriele Gugliotta, Lisa Argnani, Martina Cantelli, et al.
Blood|March 24, 2007
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemiaAlessandro M Vannucchi, Elisabetta Antonioli, Paola Guglielmelli, et al.
Leukemia Research|July 19, 2011
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemiaLuigi Gugliotta, Alessia Tieghi, Giovanni Tortorella, et al.
Leukemia|December 2, 2020
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGSSimona Soverini, Margherita Martelli, Luana Bavaro, et al.
Haematologica|February 13, 2008
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatmentsValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2014
Differences among young adults, adults and elderly chronic myeloid leukemia patientsF Castagnetti, G Gugliotta, M Baccarani, et al.
Pageof 47